Pliant Therapeutics Share Price Today

Pliant Therapeutics presents PLN-101095 data at SITC 2026

Pliant Therapeutics presented preclinical and clinical data for PLN-101095 at the 2026 SITC Annual Meeting. Preclinical data showed blocking integrins αvβ8 and αvβ1 with anti-PD-1 improved anti-tumor activity and survival. Clinical biomarker analysis linked early immune activation during monotherapy to subsequent response with pembrolizumab. FORTIFY Phase 1b trial is expanding to include NSCLC, high tumor mutational burden, and clear cell renal cell carcinoma cohorts.

Pliant Therapeutics appoints David Raben as chief medical officer

Pliant Therapeutics appointed David Raben as Chief Medical Officer on September 30, 2026. Raben brings over 30 years of experience in oncology drug development and clinical care. He previously served as CMO at Bicara Therapeutics and held leadership roles at Amgen and Genentech. The company granted him options for 575,000 shares under Nasdaq Listing Rule 5635(c)(4). Appointment supports advancement of lead asset PLN-101095 ahead of 2027 trial readouts.

Pliant Therapeutics secures FDA Fast Track for PLN-101095 in solid tumors

Pliant Therapeutics receives FDA Fast Track designation for PLN-101095 plus pembrolizumab for ICI-refractory solid tumors. The Phase 1a/1b FORTIFY trial data is expected in 2027.

Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs

Pliant Therapeutics narrowed its Q2 2026 net loss to $22.4 million from $43.3 million year-over-year, driven by reduced operating expenses following the termination of its bexotegrast program. The company holds $159.6 million in cash, providing runway into the second half of 2028, while advancing its lead oncology candidate PLN-101095 in the FORTIFY Phase 1b trial.

Thredd and Pliant launch U.S. commercial credit program

Thredd and Pliant have launched a commercial credit program in the U.S., leveraging Thredd's AI-first processing platform and Coastal's bank sponsorship. The live Visa network program follows a late 2025 soft rollout, enabling American businesses to access Pliant's integrated spend management and credit issuance tools previously available only in Europe.

Pliant enters U.S. market via Coastal partnership to expand B2B payments

Pliant has launched in the U.S. through a partnership with Coastal, enabling compliant market entry and long-term scalability. Coastal will serve as the sponsor bank, supporting Pliant’s agent-based issuing structures and expansion across the U.S. banking ecosystem. This move accelerates Pliant’s global growth strategy in the B2B payments sector.